Cochrane · systematic review · CD013604
Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer
Uneno, Y, Imura, H, Makuuchi, Y, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 66.7%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Pre‐emptive antifungal therapy versus empirical antifungal therapy
Population: people with cancer who have febrile neutropenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Pre‐emptive antifungal therapy vs empirical antifungal therapy | RR 0.97 [0.72, 1.3] | 6 studies · 1459 participants | Low Downgraded: risk of bias, inconsistency, indirectness |
Mortality ascribed to fungal infection Pre‐emptive antifungal therapy vs empirical antifungal therapy | RR 0.92 [0.45, 1.89] | 5 studies · 1407 participants | Low Downgraded: risk of bias, inconsistency, indirectness |
Proportion of antifungal agent use (other than prophylactic use) Pre‐emptive antifungal therapy vs empirical antifungal therapy | RR 0.71 [0.47, 1.05] | 7 studies · 1480 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |
Duration of antifungal use (days) Pre‐emptive antifungal therapy vs empirical antifungal therapy | no estimate extracted | 3 studies · 764 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |
Invasive fungal infection detection Pre‐emptive antifungal therapy vs empirical antifungal therapy | RR 1.7 [0.71, 4.05] | 7 studies · 1480 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |
Adverse effects Pre‐emptive antifungal therapy vs empirical antifungal therapy | no estimate extracted | 4 studies · 1074 participants | Very low Downgraded: risk of bias, inconsistency, indirectness |